Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Marc Espié"'
Autor:
Michel Marty, Marc Espié, Barbara Pistilli, Sylvie Giacchetti, Junheng Gao, Enora Laas, Sandrine Tury, F Reyal, Brice Aouchiche, Jean-Yves Pierga, E. Brain, Martin J. Edelman, Bernard Asselain, Gabriel Benchimol, Marick Laé, Xiaofei Wang, Anne-Sophie Hamy
Publikováno v:
Journal of Clinical Oncology. 37:624-635
PURPOSE The overexpression of cyclooxygenase 2 (COX-2) gene, also known as prostaglandin-endoperoxide synthase 2 ( PTGS2), occurs in breast cancer, but whether it affects response to anticox drugs remains unclear. We investigated the relationships be
Autor:
F-C Bidard, C. Simondi, Delphine Loirat, Frédérique Berger, Véronique Diéras, J-Y Pierga, PH Cottu, William Jacot, J-M Ferrero, Thomas Bachelot, Marc Espié, Catherine Alix-Panabières, Sylvain Ladoire, Sylvain Dureau, C. Levy, H Bourgeois, Florence Dalenc, Joseph Gligorov, A. Gonçalves, E. Brain, H. Naman
Publikováno v:
Cancer Research. 79:GS3-07
Background: In ER+ HER2- metastatic breast cancer (MBC) patients, the clinical choice between 1st line hormone therapy (HT, the recommended option) or chemotherapy (CT) is based on the absence of “visceral crisis” or adverse prognostic factors, w
Autor:
Stéphanie Catala, Laetitia Gambotti, C. Faure Mercier, L. Venat-Bouvet, Xavier Pivot, Sophie Paget-Bailly, Iris Pauporté, J-M Grouin, Christelle Jouannaud, J-Y Pierga, Julie Henriques, Maria Rios, David Khayat, Gilles Romieu, P. Kerbrat, Thomas Bachelot, P. Fumoleau, Daniel Serin, Marc Espié, Marc Debled, Sophie Abadie-Lacourtoisie, J.P. Jacquin, Alain Lortholary, L. Cany
Publikováno v:
Cancer Research. 79:GS2-07
Since 2005, 12 months of trastuzumab added to chemotherapy alone is the standard of care in patients with HER2-positive breast cancer. PHARE ('Protocol for Herceptin® as Adjuvant therapy with Reduced Exposure') is the first trial comparing a reducti
Autor:
S.ophie Guillerm, Caroline Cuvier, Eva Marchand, Laurent Quero, Marc Espié, E. Bourstyn, Henri Lorphelin, Luis Augusto Teixeira, Ramona Itti, Sylvie Giacchetti, Laurence Cahen-Doidy, Christophe Hennequin, Mouna Labidi
Publikováno v:
Clinical breast cancer. 22(1)
Purpose To evaluate outcomes and post-operative toxicities after intra-operative radiotherapy (IORT) in elderly women Population Women older than 65 years, with an infiltrating ductal breast cancer ≤3 cm, expressing Estrogen receptors (ER+) without
Autor:
Philippe Bertheau, Lucie Biard, Brigitte Poirot, Christos Sotiriou, Luis Augusto Teixeira, Jacqueline Lehmann-Che, Matthieu Resche-Rigon, Patricia de Cremoux, Pascal Merlet, Fatiha Bouhidel, David Groheux, Marc Espié
Publikováno v:
Oncotarget
Oncotarget, 9 (23
Oncotarget, 9 (23
Background: The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic pro
Autor:
Florian Scotté, Alain Toledano, Ladan Duvillié, Dominique Spaeth, Isabelle Pithois Merli, Stéphanie Perot, Elisabeth Luporsi, Roland Bugat, Marc Espié
Publikováno v:
Supportive Care in Cancer. 25:973-982
This report describes the results of an observational, retrospective cohort study, evaluating the use of iron sucrose (IS) and red blood cell (RBC) transfusions in patients with cancer in routine clinical practice in France. A parallel investigated c
Autor:
Ahmad Awada, Marc Espié, Miguel Martín, Mafalda Oliveira, Philippe Aftimos, Pilar Lardelli, Eva E.M. Fernández-García, Sonia Extremera, Javier Cortes, Sara López-Tarruella, Suzette Delaloge
Publikováno v:
Clinical Breast Cancer. 16:364-371
Background Preclinical and clinical data suggest that xeroderma pigmentosum G gene (XPG) status might predict trabectedin efficacy. This phase 2 study evaluated the efficacy of trabectedin at a dose of 1.3 mg/m 2 as a 3-hour intravenous infusion ever
Autor:
Marc Espié, Lina Bolotine, Jean-Charles Soria, Anne Laprie, Lucie Karayan-Tapon, Jocelyn Céraline, Henri Roché, Patricia de Cremoux, Jean-Jacques Mazeron, Sylvie Negrier, Gilles Calais, Gérard Bastian
Publikováno v:
Bulletin du Cancer. 103:719-729
Autor:
Morad El Bouchtaoui, Marianne Ziol, Guilhem Bousquet, Anne Janin, Irmine Loisel-Ferreira, Bruno Cassinat, Carèle Fedronie, Christophe Leboeuf, Jean-Jacques Kiladjian, Jean-Paul Feugeas, Rachida Ait El Far, Chrystophe Ferreira, Marcio Do Cruzeiro, Géraldine Falgarone, Marc Espié
Publikováno v:
Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2019, 25 (14), pp.4504-4515. ⟨10.1158/1078-0432.CCR-18-3261⟩
Clinical Cancer Research, American Association for Cancer Research, 2019, 25 (14), pp.4504-15. ⟨10.1158/1078-0432.CCR-18-3261⟩
Clinical Cancer Research, 2019, 25 (14), pp.4504-15. ⟨10.1158/1078-0432.CCR-18-3261⟩
Clinical Cancer Research, American Association for Cancer Research, 2019, 25 (14), pp.4504-4515. ⟨10.1158/1078-0432.CCR-18-3261⟩
Clinical Cancer Research, American Association for Cancer Research, 2019, 25 (14), pp.4504-15. ⟨10.1158/1078-0432.CCR-18-3261⟩
Clinical Cancer Research, 2019, 25 (14), pp.4504-15. ⟨10.1158/1078-0432.CCR-18-3261⟩
Purpose: The genesis of all cancers results from an accumulation of mutations, constitutional and/or acquired when induced by external mutagenic factors. High-speed technologies for genome sequencing have completely changed the study of disease genet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8973d8fdf7d69c4ca064aae5618014db
https://www.hal.inserm.fr/inserm-02543896
https://www.hal.inserm.fr/inserm-02543896
Autor:
Xiao-Mei Li, A Okyar, Y Chang-Marchand, Francis Lévi, J Machowiak, Marc Espié, Sylvie Giacchetti, J Arrondeau, N Ozturk, Caroline Cuvier
Publikováno v:
Cancer Research. 77:P4-06
Background The molecular circadian clock regulates mTOR activity, the main target of EV. EV use is hampered by adverse events in MBC patients (pts). Knowing the optimal timing of EV oral intake could improve tolerability, thus compliance and treatmen